Glucotrack, INC. (GCTK) — SEC Filings

Overview

Glucotrack, INC. (GCTK) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 31, 2025: Glucotrack, Inc. filed an 8-K on December 29, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and Regulation FD disclosures. The filing also includes financial statements and exhibits. The company, formerly known as Integrity Applications, Inc., is incorp

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 4 bearish, 44 neutral, 2 mixed. The dominant filing sentiment for Glucotrack, INC. is neutral.

Filing Type Overview

Glucotrack, INC. (GCTK) has filed 38 8-K, 3 10-Q, 2 DEFA14A, 1 S-1/A, 2 DEF 14A, 1 S-1, 2 8-K/A, 1 10-K with the SEC between Jan 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (50)

• 8-K Filing — 8-K · Apr 14, 2026
• 8-K Filing — 8-K · Mar 27, 2026
• Glucotrack, Inc. Files 8-K with Key Agreements and Disclosures — 8-K · Dec 31, 2025 Risk: medium
  Glucotrack, Inc. filed an 8-K on December 29, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and Regulation FD dis
• Glucotrack, Inc. Files 8-K — 8-K · Dec 29, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on December 29, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, for
• Glucotrack's Losses Widen Amid Clinical Progress, Liquidity Concerns — 10-Q · Nov 13, 2025 Risk: high
  Glucotrack, Inc. (GCTK) reported a net loss of $15.76 million for the nine months ended September 30, 2025, an increase from $12.503 million in the same period
• Glucotrack, Inc. Files 8-K on Shareholder Vote Matters — 8-K · Nov 7, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on November 7, 2025, reporting on a submission of matters to a vote of security holders. The filing details the company's corporat
• Glucotrack, Inc. Reports on Shareholder Vote Matters — 8-K · Nov 6, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on November 6, 2025, reporting on matters submitted to a vote of security holders as of October 31, 2025. The filing indicates a s
• 8-K Filing — 8-K · Nov 3, 2025
• Glucotrack Inc. Files Definitive Additional Materials — DEFA14A · Oct 31, 2025 Risk: low
  Glucotrack, Inc. filed a DEFA14A on October 31, 2025, indicating it is a definitive additional material filing. The company, formerly known as Integrity Applica
• Glucotrack, Inc. Files 8-K — 8-K · Oct 29, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on October 29, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, form
• Glucotrack, Inc. Files 8-K: Regulation FD & Financials — 8-K · Oct 28, 2025 Risk: low
  On October 28, 2025, Glucotrack, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and includes Financial Statements and Exhibits
• Glucotrack Inc. Files Definitive Proxy Materials — DEFA14A · Oct 15, 2025 Risk: low
  Glucotrack, Inc. filed a DEFA14A on October 15, 2025, related to its proxy statement. The filing indicates no fee was required for this submission, and it was f
• Glucotrack Secures $20M Equity Line, Faces 2,203% Dilution Risk — S-1/A · Oct 8, 2025 Risk: high
  Glucotrack, Inc. (GCTK) filed an S-1/A on October 8, 2025, detailing a committed equity financing facility of up to $20.0 million with Sixth Borough Capital Fun
• Glucotrack Seeks Shareholder Nod for 20%+ Stock Issuance to Sixth Borough — DEF 14A · Oct 3, 2025 Risk: medium
  Glucotrack, Inc. (GCTK) is seeking stockholder approval for the issuance of common stock to Sixth Borough Capital Fund, LP, which could represent over 20% of th
• Glucotrack Files S-1 for 20M Share Resale, Signaling Major Dilution Risk — S-1 · Sep 29, 2025 Risk: high
  Glucotrack, Inc. (GCTK) filed an S-1 on September 29, 2025, for the resale of up to 20,060,000 shares of common stock by Sixth Borough Capital Fund, LP. This in
• Glucotrack, Inc. Enters Material Agreement, Reports Equity Sales — 8-K · Sep 12, 2025 Risk: medium
  On September 12, 2025, Glucotrack, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported unregist
• Glucotrack, Inc. Files 8-K on Material Agreement & Equity Sales — 8-K · Sep 11, 2025 Risk: medium
  On September 11, 2025, Glucotrack, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The filing al
• Glucotrack's Losses Widen Amid Clinical Progress, Capital Raise — 10-Q · Aug 14, 2025 Risk: high
  Glucotrack, Inc. (GCTK) reported a net loss of $11.589 million for the six months ended June 30, 2025, a significant increase from the $7.416 million loss in th
• Glucotrack, Inc. Files 8-K — 8-K · Aug 6, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on August 6, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, former
• Glucotrack, Inc. Files 8-K with Financials — 8-K · Jul 31, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on July 31, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Integ
• Glucotrack Files Amendment to Certifying Accountant Report — 8-K/A · Jul 25, 2025 Risk: low
  Glucotrack, Inc. filed an amendment (8-K/A) on July 25, 2025, to its report originally filed on July 18, 2025. This amendment pertains to changes in the registr
• Glucotrack Changes Auditors — 8-K · Jul 24, 2025 Risk: low
  Glucotrack, Inc. announced on July 18, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered public account
• Glucotrack, Inc. Files 8-K — 8-K · Jul 8, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on July 8, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific
• Glucotrack, Inc. Files 8-K with Corporate Updates — 8-K · Jun 25, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on June 25, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing details the company's
• Glucotrack, Inc. Files 8-K with Corporate Updates — 8-K · Jun 16, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on June 16, 2025, reporting events as of June 13, 2025. The filing indicates amendments to its Articles of Incorporation or Bylaws
• Glucotrack, Inc. Files 8-K — 8-K · Jun 12, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on June 12, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as In
• Glucotrack, Inc. Files 8-K — 8-K · Jun 4, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on June 4, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Int
• Glucotrack, Inc. Files 8-K on Officer/Director Changes — 8-K · May 23, 2025 Risk: medium
  Glucotrack, Inc. filed an 8-K on May 23, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certai
• Glucotrack, Inc. Files 8-K Report — 8-K · May 20, 2025 Risk: low
  On May 20, 2025, Glucotrack, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update or disclosur
• Glucotrack, Inc. Files Q1 2025 10-Q Report — 10-Q · May 14, 2025 Risk: low
  Glucotrack, Inc. filed its quarterly report for the period ending March 31, 2025. The company, previously known as Integrity Applications, Inc., is based in Rut
• Glucotrack, Inc. Files 8-K with Financials — 8-K · May 13, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on May 13, 2025, reporting under Regulation FD and including financial statements and exhibits. The company, formerly known as Int
• 8-K Filing — 8-K · Apr 29, 2025
• Glucotrack Files DEF 14A on Executive Compensation — DEF 14A · Apr 28, 2025 Risk: low
  Glucotrack, Inc. filed a DEF 14A on April 28, 2025, detailing executive compensation and stock awards for the fiscal year ending December 31, 2024. The filing i
• Glucotrack, Inc. Files 8-K with Financial Updates — 8-K · Apr 16, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on April 16, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing confirms the company'
• Glucotrack Faces Delisting Concerns — 8-K · Apr 4, 2025 Risk: high
  Glucotrack, Inc. filed an 8-K on April 4, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event r
• Glucotrack, Inc. Files 8-K — 8-K · Apr 3, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on April 3, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Integ
• 10-K Filing — 10-K · Mar 31, 2025
• Glucotrack, Inc. Files 8-K: Reg FD & Financials — 8-K · Mar 19, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on March 19, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as I
• Glucotrack Reports Unregistered Equity Sales — 8-K · Mar 13, 2025 Risk: medium
  Glucotrack, Inc. filed an 8-K on March 13, 2025, reporting unregistered sales of equity securities on March 11, 2025. The filing does not disclose specific deta
• Glucotrack, Inc. Files 8-K — 8-K · Feb 26, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on February 26, 2025, to report on Regulation FD disclosures and financial statements. The filing confirms the company's name as G
• Glucotrack, Inc. Files 8-K — 8-K · Feb 14, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on February 14, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as Integrity Ap
• Glucotrack, Inc. Signs Material Definitive Agreement — 8-K · Feb 5, 2025 Risk: medium
  On February 4, 2025, Glucotrack, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement, the counterp
• Glucotrack, Inc. Files 8-K with Corporate Updates — 8-K · Feb 4, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on February 4, 2025, reporting an amendment to its Articles of Incorporation or Bylaws, a Regulation FD disclosure, and other even
• Glucotrack, Inc. Files 8-K with Financials — 8-K · Jan 30, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on January 30, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as In
• Glucotrack Director Departs, CEO Appointed to Board — 8-K · Jan 29, 2025 Risk: medium
  Glucotrack, Inc. announced on January 27, 2025, the departure of Director David J. Glickman. The company also elected Dr. Shlomo Ben-Haim as a new director and
• Glucotrack, Inc. Files 8-K — 8-K · Jan 21, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on January 21, 2025, reporting a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
• Glucotrack Files Amendment on Equity Sales — 8-K/A · Jan 14, 2025 Risk: medium
  Glucotrack, Inc. filed an amendment (8-K/A) on January 14, 2025, regarding unregistered sales of equity securities that occurred on January 6, 2025. The filing
• Glucotrack Reports Unregistered Equity Sale — 8-K · Jan 13, 2025 Risk: medium
  Glucotrack, Inc. reported on January 6, 2025, an unregistered sale of equity securities. The filing does not disclose the specific number of shares sold or the
• Glucotrack, Inc. Files 8-K for Regulatory Disclosure — 8-K · Jan 8, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on January 8, 2025, reporting events from January 7, 2025. The filing primarily concerns Regulation FD Disclosure and Financial St
• Glucotrack, Inc. Files 8-K with Corporate Updates — 8-K · Jan 7, 2025 Risk: low
  Glucotrack, Inc. filed an 8-K on January 7, 2025, reporting events as of January 3, 2025. The filing indicates amendments to its Articles of Incorporation or By

Risk Profile

Risk Assessment: Of GCTK's 45 recent filings, 5 were flagged as high-risk, 10 as medium-risk, and 30 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Glucotrack, INC.'s most recent 10-Q filing (Nov 13, 2025):

• Net Income: -$15.76M
• Cash Position: $7.87M
• Total Debt: $5.54M

Key Executives

• Paul Goode
• David Mannheim, Esq.
• David J. Glickman
• Dr. Shlomo Ben-Haim

Industry Context

The diabetes management market is characterized by rapid technological advancement, particularly in continuous glucose monitoring (CGM) and implantable devices. Companies are focused on improving accuracy, reducing invasiveness, and extending device longevity. Key trends include integration with insulin delivery systems and data analytics for personalized treatment.

Top Tags

disclosure (9) · financials (6) · 8-K (5) · corporate-governance (5) · financial-statements (5) · material-agreement (4) · regulatory (4) · Medical Devices (4) · regulatory-filing (4) · equity-sale (3)

Key Numbers

• SEC File Number: 001-41141 — Identifies the company's filing with the SEC
• IRS EIN: 98-0668934 — Company's tax identification number
• Net Loss: $15.76M — Increased from $12.503M in prior year period, highlighting widening losses.
• Accumulated Deficit: $148.21M — Indicates significant historical losses and raises going concern doubts.
• Cash and Cash Equivalents: $7.87M — Increased from $5.617M, but still low given burn rate and development needs.
• Public Offering Proceeds: $10.7M — Key financing source for the period, vital for operations.
• MARD: 7.7% — Excellent accuracy in First-In-Human clinical study, a positive technical indicator.
• Total Liabilities: $5.54M — Significantly reduced from $18.932M, primarily due to derivative liability changes.
• R&D Expenses: $8.19M — Increased from $7.80M, reflecting ongoing investment in product development.
• Sensor Longevity Target: 3 years — Key product feature for the implantable CBGM, if successful.
• Committed Equity Financing: $20.0M — Potential capital Glucotrack may receive from Sixth Borough
• Shares Registered for Resale: 20,060,000 — Represents a significant potential increase in outstanding shares
• Dilution Percentage: 2,203% — Percentage of current outstanding shares represented by the registered shares, indicating severe dilution risk
• Last Reported Stock Price: $7.45 — GCTK's closing price on Nasdaq Capital Market on October 7, 2025
• Shares Outstanding: 910,688 — Total common stock outstanding as of October 8, 2025, prior to potential dilution

Related Companies

DXCM · ABT

Frequently Asked Questions